Search

Standing together in support of improved access to obesity care

Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.

A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US

A Moment To Reflect on the Evolving Approach for Diabetes Management

Full results from EMPERIAL exercise ability trials presented

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Our forward-looking approach drives breakthroughs

Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.

SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US

Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US

Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.

A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care

Immunology

Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Cardiologists at the Heart of Cardio-Renal-Metabolic Care

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

Pets

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Partnering for Innovative Pet Therapeutics

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers